SIETES :: 93161 citas

Resultados de la búsqueda por FRAUDE REFINAR BÚSQUEDA

1.

Villarreal A. PharmaMar: cómo un improbable fármaco anticovid ha generado 1.000 M en bolsa. El Confidencial 2020:5. [Ref.ID 103774]

2.

Ostengaard L, Lundh A, Tjørnhøj-Thomsen T, Abdi S, Gelle MHA, Stewart LA, Boutron I, Hróbjartsson A. nfluence and management of conflicts of interest in randomised clinical trials: qualitative interview study. BMJ 2020;371:27 de octubre. [Ref.ID 103760]

3.

Samper E. Remdesivir: el culebrón de un fármaco sobrevalorado que parece acercarse a su fin. eldiario.es 2020:19 de octubre. [Ref.ID 103750]

4.

Sharrets J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer risk associated with lorcaserin — The FDA’s review of the CAMELLIA-TIMI 61 trial. N Engl J Med 2020;383:10 de septiembe. [Ref.ID 103713]

5.

Borraz M, Ferrer S. Historia de un escándalo: una empresa sospechosa y el estudio que sacudió a la prestigiosa revista 'The Lancet' . eldiario.es 2020:6 de junio. [Ref.ID 103642]

6.

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19. N Engl J Med 2020;382:18 de junio. [Ref.ID 103602]

7.

Di Maio M, Audisio M, Cardone C, De Luca E, Gargiulo P, Zichi C, Perrone F. The use of not-negative conclusions to describe results of formally negative trials presented at oncology meetings. JAMA Oncology 2020:1. [Ref.ID 103598]

8.

Dyer O. Cochrane reviewer sues Roche for claiming Tamiflu could slow flu pandemic. BMJ 2020;368:31 de enero. [Ref.ID 103541]

9.

Simó Miñana J. Guerras médicas: a propósito del ensayo EXCEL . Salud, dinero y atención primaria 2019:15 de diciembre. [Ref.ID 103225]

10.

Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]

11.

12.

Taylor P. J&J hit by $8bn judgment for man claiming breast growth due to Risperdal. PMLiVE 2019:9 de octubre. [Ref.ID 103192]

13.

Taylor P. Servier faces manslaughter trial over weight loss drug deaths. Drug shown to damage heart and thought to cause death. PMLiVE 2019:24 de septiembre. [Ref.ID 103181]

14.

Khan MS, Lateef N, Siddiqi TJ, Rehmab KA, Alnaimat S, Khan SU, Riaz H, Murad H, Mandrola J, Doukky R, Krasuski RA. Level and prevalence of spin in published cardiovascular randomized clinical trial reports with statistically nonsignificant primary outcomes. A systematic review. JAMA Network Open 2019:3 de mayo. [Ref.ID 103114]

15.

Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]

16.

Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) — Pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med 2019:10 de abril. [Ref.ID 103090]

17.

Agarwal A, Ioannidis JPA. PREDIMED trial of Mediterranean diet: retracted, republished, still trusted?. BMJ 2019;364:7 de febrero. [Ref.ID 103032]

18.

Anónimo. Chair Of FDA’s opioid advisory committee says agency manipulated process to approve controversial opioid. DIA Daily 2019:9. [Ref.ID 103006]

19.

Healy D. The Goetzsche affair. Dr. David Healy (blog) 2018:5 de noviembre. [Ref.ID 102892]

20.

Anónimo. Johnson & Johnson begins settling consumer lawsuits over marketing of defective artificial hips. DIA Daily 2018:1. [Ref.ID 102874]